EGFR and head and neck squamous cell carcinoma: Improving clinical response rates will involve (1) identifying SCCHN patients who are likely to respond to EGFR-targeted therapies, (2) developing effective combinations of targeted therapies, and (3) correctly identifying patients who will respond to specific targeted agents applied alone or in combination.